RxDoctor Payments Data

Andrea Littlefield, PA

Surgical · Oak Ridge, TNNPI 1801417613

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations.

$2,840in general payments, 2019–2025

Across 85 payments — averaging $33.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$461
  • C. R. Bard, Inc. & Subsidiaries$398
  • Sumitomo Pharma America, Inc.$366
  • Myriad Genetic Laboratories, Inc.$204
  • AbbVie$192
  • Urogen Pharma, Inc.$190
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$2,840100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,840 in reported general payments places this provider in the 85th percentile of 206 surgical providers in Tennessee.

See all surgical providers in Tennessee

Medicare billing

Part B allowed, 2024
$256,345
Medicare patients
988
Services billed
24,508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron207$172,871
MyrbetriqMirabegron111$80,852
Estradiol88$5,927
Tamsulosin Hcl397$5,631
Alfuzosin Hcl ErAlfuzosin Hcl158$4,028
Testosterone Cypionate54$3,229
Testosterone15$2,906
Trimethoprim45$2,847
Solifenacin Succinate67$2,246
NitrofurantoinNitrofurantoin Macrocrystal42$1,939
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst108$1,454
Desmopressin Acetate12$1,129
Oxybutynin Chloride ErOxybutynin Chloride30$1,027
Cefdinir59$672
Doxycycline Hyclate37$577

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$366$172,871207 claims
Astellas Pharma US IncMyrbetriq$64$80,852111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 206 surgical providers in Tennessee.

Other surgical in Oak Ridge

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →